Everest Organics Ltd
₹ 421
2.00%
12 Sep
- close price
- Market Cap ₹ 409 Cr.
- Current Price ₹ 421
- High / Low ₹ 477 / 112
- Stock P/E 65.9
- Book Value ₹ 72.0
- Dividend Yield 0.00 %
- ROCE 1.76 %
- ROE -2.23 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.85 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.94% over past five years.
- Company has a low return on equity of -0.82% over last 3 years.
- Company has high debtors of 202 days.
- Promoter holding has decreased over last 3 years: -13.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 181 | |
91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 166 | |
Operating Profit | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 15 |
OPM % | 6% | 7% | 6% | 6% | 6% | 11% | 12% | 13% | 3% | 1% | 6% | 5% | 8% |
1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 | |
Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
Depreciation | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
Profit before tax | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 5 |
Tax % | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | |
1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 6 | |
EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 6.81 | ||
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | -1% |
3 Years: | -7% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 204% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 41% |
1 Year: | 203% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | -1% |
Last Year: | -2% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 |
Reserves | -5 | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 |
26 | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | |
35 | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 107 | |
Total Liabilities | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 |
24 | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 52 | 51 | |
CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 21 | 21 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
41 | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 152 | |
Total Assets | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | 16 | -5 | |
-3 | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | -13 | -5 | |
2 | -2 | -0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | -3 | 16 | |
Net Cash Flow | 0 | -0 | 0 | 0 | -0 | 1 | 0 | -0 | -1 | 0 | 0 | 6 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 |
Inventory Days | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 168 |
Days Payable | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 355 |
Cash Conversion Cycle | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 15 |
Working Capital Days | -43 | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -20 | 3 |
ROCE % | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Sep - Everest Organics Limited has informed about publication of Notice of 32nd Annual General Meeting.
-
Letter To Members
5 Sep - Annual Report FY2024-25 online; AGM on 27 Sep 2025; web-link and email-update instructions.
- Reg. 34 (1) Annual Report. 4 Sep
- 32Nd Annual General Meeting -Notice 4 Sep
-
General Updates-Newspaper Publication
30 Aug - Everest Organics Limited has informed about the copy of newspaper publications.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jul 2020TranscriptNotesPPT
Product Profile:
a) APIs:[1]
Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia
and Gout, Anti Thrombotic, Anti Fungal,
Anti Viral, Anti Emetics, Anti Diabetic,
Insomnia, Skeletal muscle relaxant,
Overactive Bladder, Rhino-Conjunctivitis,
etc.
b) Intermediates:[2]
Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate, Rivaroxaban, Itraconazole, Omeprazole, Pantoprazole, Rabeprazole, Esomeprazole, Pemetrexed, Pregabalin, Hydroxy, Chloro compound,
Sulphide, Pyrazine, Gancyclovir, Apixaban, Aprepitant, Bilastine, etc.
c) By Products:[2]
Ammonium Sulphate, Sodium Nitrite, Di
Sodium Orthophosphate, Di Ammonium
Phosphate